Targeting CD19 in Autoimmune Neuropathy: Case Report Insights
Living RheumTargeting CD19 in Autoimmune Neuropathy: Case Report Insights
Reimagining Autoimmune Care with CAR-Based Cell Therapies
Living RheumReimagining Autoimmune Care with CAR-Based Cell Therapies
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Project Oncology®Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Essential Biomarkers for Assessing and Treating IgA Nephropathy
Clinician's RoundtableEssential Biomarkers for Assessing and Treating IgA Nephropathy
IgA Nephropathy Care: A Shift Toward Proactive, Targeted Treatment
Clinician's RoundtableIgA Nephropathy Care: A Shift Toward Proactive, Targeted Treatment
Building a Multidisciplinary Approach to IgA Nephropathy Care
Clinician's RoundtableBuilding a Multidisciplinary Approach to IgA Nephropathy Care
- advertisement
Identifying a Key Cause of Hard to Control Diabetes
CME/CEIdentifying a Key Cause of Hard to Control Diabetes
Treatment of a Broader Population of Patients With DMD
CME/CETreatment of a Broader Population of Patients With DMD
New Frontiers in the Treatment of DMD Across the Age Spectrum
CME/CENew Frontiers in the Treatment of DMD Across the Age Spectrum
Recent Guidelines Updates: Implications to Practice
MinuteCE®Recent Guidelines Updates: Implications to Practice
Advancing Cystic Fibrosis: Addressing Disparities, Challenging Perceptions, and Innovating Patient-Centered Care
CME/CEAdvancing Cystic Fibrosis: Addressing Disparities, Challenging Perceptions, and Innovating Patient-Centered Care
- advertisement
Aligning Efficacy With Patient Goals: The Role of SCIg in CIDP Maintenance
Medical Industry FeatureAligning Efficacy With Patient Goals: The Role of SCIg in CIDP Maintenance
Managing the Severe Consequences of PNH With Targeted Therapy
Medical Industry FeatureManaging the Severe Consequences of PNH With Targeted Therapy
From IVIg to SCIg: Rethinking Long-Term CIDP Therapy
Medical Industry FeatureFrom IVIg to SCIg: Rethinking Long-Term CIDP Therapy
Fibrodysplasia Ossificans Progressiva: Mechanism of Disease
Medical Industry FeatureFibrodysplasia Ossificans Progressiva: Mechanism of Disease
Ph+ CML and Treatment Adherence: Rethinking Nilotinib Formulations and Fasting Restrictions
Medical Industry FeaturePh+ CML and Treatment Adherence: Rethinking Nilotinib Formulations and Fasting Restrictions
Biomarker Predicts Response to BCMA CAR T-Cell Therapy in Multiple Myeloma
Medical Industry FeatureBiomarker Predicts Response to BCMA CAR T-Cell Therapy in Multiple Myeloma